Electric modulation of sympathetic nervous system

• US 20070225768A1
• Filed: 05/17/2007
• Published: 09/27/2007
• Est. Priority Date: 03/22/2002
• Status: Active Grant

• Current Assignee: Leptos Biomedical, Inc. (Abbott Laboratories Incorporated)
• Original Assignee: Leptos Biomedical, Inc. (Abbott Laboratories Incorporated)
• Inventors: Dobak, John
• Granted Patent: US 8,024,035 B2
• Time in Patent Office: Days
• US Class Current: 607/2
• CPC Class Codes: A61N 1/36007 of urogenital or gastrointestinal organs, e.g. for incontinence control
• CPC Class Codes: A61N 1/36017 with leads or electrodes penetrating the skin
• CPC Class Codes: A61N 1/36071 Pain
• CPC Class Codes: A61N 1/36085 Eating disorders or obesity

Abstract

A method is described for the treatment of obesity or other disorders, by electrical activation or inhibition of the sympathetic nervous system. This activation or inhibition can be accomplished by electrically stimulating the greater splanchnic nerve or other portion of the sympathetic nervous system using an implantable pulse generator. This nerve activation can result in reduced food intake and increased energy expenditure. Reduced food intake may occur through a variety of mechanisms that reduce appetite and cause satiety. Increased adrenal gland hormone levels will result in increased energy expenditure. Fat and carbohydrate metabolism, which are also increased by sympathetic nerve activation, will accompany the increased energy expenditure.

Claims

1. A method for treating obesity, comprising:

monitoring a patient parameter; and

electrically activating a splanchnic nerve in said patient so as to achieve a desired change in said monitored parameter;

wherein the splanchnic nerve is selected from the group consisting of the greater splanchnic nerve, the lesser splanchnic nerve, and the least splanchnic nerve;

wherein said monitored parameter comprises an arterial blood pressure; and

wherein said electrically activating comprises activating the sympathetic nervous system with stimulation parameters that keep the arterial blood pressure within safe limits.

2. A method for treating a medical disorder, comprising:

monitoring a vital sign and a second parameter in a patient; and

electrically activating the sympathetic nervous system of said patient so as to achieve a desired change in said second parameter.

3. The method recited in claim 2, wherein:

said medical disorder being treated comprises obesity;

said vital sign comprises an arterial blood pressure;

said second parameter comprises a plasma catecholamine level;

said electrically activating comprises activating the splanchnic nerve to achieve an increased plasma catecholamine level; and

said electrical activation has a signal-on time no greater than a signal-off time.

4. The method recited in claim 2, wherein:

said medical disorder being treated comprises obesity;

said vital sign comprises an arterial blood pressure;

said second parameter comprises a plasma ghrelin level;

said electrically activating comprises activating of a splanchnic nerve to achieve a decreased plasma ghrelin level; and

said electrically activating has a signal-on time no greater than a signal-off time.

5. The method recited in claim 2, wherein:

said medical disorder being treated comprises obesity;

said vital sign comprises an arterial blood pressure;

said second parameter comprises a plasma glucose level;

said electrically activating comprises activating the splanchnic nerve to achieve an increased plasma glucose level; and

said electrically activating has a signal-on time no greater than a signal-off time.

6. The method recited in claim 2, wherein:

said medical disorder being treated as Type II diabetes;

said vital sign comprises an arterial blood pressure;

said second parameter comprises an insulin level;

said electrically activating comprises activating the splanchnic nerve to achieve a decreased insulin level; and

said electrically activating has a signal-on time no greater than a signal-off time.